Evaxion Biotech (NASDAQ: EVAX) files Q2 2025 financial statements on 6-K

Rhea-AI Filing Summary

Evaxion Biotech A/S submitted a Form 6-K as a foreign private issuer, providing investors with updated information on its business. The filing states that the company has furnished unaudited condensed consolidated interim financial statements and a management discussion and analysis for the fiscal quarter ended June 30, 2025. These materials are included as exhibits and are also incorporated by reference into several of Evaxion’s existing registration statements. The report is signed by the company’s Chief Executive Officer, Birgitte Rønø, and Chief Financial Officer, Thomas Frederik Schmidt, confirming management’s authorization of this quarterly disclosure.

0001828253 June 30, 2025 false --12-31 Q2 2025

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-39950

Evaxion Biotech A/S

(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f

DK-2970 Hoersholm

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒               Form 40-F ☐

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 of this report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132) and on Form F-1 (File No. 333-266050), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Furnished as Exhibits to this Report on Form 6-K is information regarding the Company’s financial results for the fiscal quarter ended June 30, 2025.

Exhibits

Exhibit
No.		Description
99.1		Unaudited Condensed Consolidated Interim Financial Statements.
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations.
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Evaxion Biotech A/S
Date: August 13, 2025	By:	/s/ Birgitte Rønø
		Birgitte Rønø
		Chief Executive Officer

Date: August 13, 2025	By:	/s/ Thomas Frederik Schmidt
		Thomas Frederik Schmidt
		Chief Financial Officer

FAQ

What did Evaxion Biotech A/S (EVAX) file in this Form 6-K?

Evaxion Biotech A/S filed a Form 6-K as a foreign private issuer, furnishing unaudited condensed consolidated interim financial statements and a management discussion and analysis for the fiscal quarter ended June 30, 2025.

Which period do the new Evaxion Biotech (EVAX) financials cover?

The financial information furnished by Evaxion Biotech A/S covers the fiscal quarter ended June 30, 2025.

How is this Evaxion Biotech (EVAX) Form 6-K used in existing registrations?

Exhibits 99.1 and 99.2 are incorporated by reference into Evaxion’s registration statements on Form S-8, Form F-3, and Form F-1, becoming part of those registration statements from the filing date.

Who signed the Evaxion Biotech A/S (EVAX) Form 6-K?

The Form 6-K was signed on behalf of Evaxion Biotech A/S by Chief Executive Officer Birgitte Rønø and Chief Financial Officer Thomas Frederik Schmidt on August 13, 2025.

What exhibits are included with this Evaxion Biotech (EVAX) Form 6-K?

The filing includes Exhibit 99.1 (unaudited condensed consolidated interim financial statements), Exhibit 99.2 (management’s discussion and analysis), and a series of Inline XBRL data files plus the cover page interactive data file.